Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 32, 2002 - Issue 2
38
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Metabolism of 10,11-dihydro-10-hydroxyimino-5H-dibenz/b, ƒ /azepine-5-carboxamide, a potent anti-epileptic drug

, , &
Pages 131-140 | Published online: 22 Sep 2008

References

  • AMBROSIO, A. F., SILVA, A. P., ARAUJO, I., MALVA, J. 0., SOARES-DA-SILVA, P., CARVALHO, A. P. and CARVALHO, C. M., 2001b, Neurotoxictneuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2–093 and BIA 2–024. European Journal of Pharmacology, 406, 191–201.
  • AMBROSIO, A. F., SILVA, A. P., MALVA, J. 0., SOARES-DA-SILVA, P., CARVALHO, A. P. and CARVALHO, C. M., 2001a, Inhibition of glutamate release by BIA 2–093 and BIA 2–024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochemical Pharmacology, 61, 1271–1275.
  • BERTILSSON, L. and TOMSON, T., 1986, Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11- epoxide: an update. Clinical Pharmacokinetics,11,177–198.
  • BRADFORD, M. M., 1976, A rapid sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein—dye binding. Analytical Biochemistry, 72, 248–254.
  • EICHELBAUM, M., TOMSON, T., TYBRING, G. and BERTILSSON, L., 1985, Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clinical Pharmacokinetics, 10, 80–90.
  • FAIGLE, J. W. and FELDMANN, K. F., 1995, Carbamazepine: chemistry and biotransformation. In R. H. Levy, R. H. Mattson and M. S. Meldrum (eds), Antiepileptk Drugs (New York: Raven), pp. 499–513.
  • FAIGLE, J. W. and MENGE, G. P., 1990, Metabolic characteristics of oxcarbazepine and their clinical significance: comparison with carbamazepine. Behavioural Neurology, 3 (suppl. 1), 21–30.
  • FELDMANN, K. F., BRECHBÜHLER, S., FAIGLE, J. W. and INnior, P., 1978, Pharmacokinetics and metabolism of GP 47 680, a compound related to carbamazepine, in animals and rats. In H Meinardi and A. J. Rowan (eds), Advances in Epileptology (Amsterdam: Swets & Zeitlinger), pp. 290–294.
  • FLESCH, G., FRANCO, E., HELL, F. and DEGEN, P. H., 1992, Determination of the R-(—) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. Journal of Chromatography, 581, 147–151.
  • GRAM, L., 1994, Clinical experience with oxcarbazepine. Epi/epsia, 35 (suppl. 3), 21–22.
  • GRANT, S. M. and FAULDS, D., 1992, Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs, 43, 873–888.
  • HAINZL, D., PARAD A. and SOARES-DA-SILNA, P., 1999, Enantio selective oxidation of 10,11- dihydro-10-hydroxy-dibenztb,flazepine-5-carboxamide, an active metabolite of oxcarbazepine, in the rat. British Journal of Pharmacology, 126, 42.
  • HAINZL, D., PARAD A. and SOARES-DA-SILVA, P., 2001, Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(—)-10,11-dihydro-1 0-hydroxy carbamazepine. Epilepsy Research, 44, 197–206.
  • LEARMONTH, D. A., BENES, J., PARADA, A., HAINZL, D., BELIAEV, A., BoNirAcio, M. J., MATIAS, P., CARRONDO, M. A., GARRETT, J. and SOARES-DA-SILVA, P., 2001, Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11- dihydro-10-oxo-5H- dibenz/b,fiazepine-5-carboxamide derivatives. European Journal of Medicinal Chemistry, 36, 227–236.
  • Li, Q., 1994, Aromatization and hydrolysis of norethisterone-3-oxirne in rabbit. Journal of Steroid Biochemistry and Molecular Biology, 49, 227–231.
  • LIN, J. and CASHMAN, J. R., 1997, Detoxication of tyramine by the flavin-containing monooxygenase: stereoselective formation of the trans-oxime. Chemical Research in Toxicology, 10, 842–852.
  • LOISEAU, P. and DuctiE, P., 1995, Carmazepine: clinical use. In R. H. Levy, R. H. Mattson and M. S. Meldrum (eds), Antiepileptk Drugs (New York: Raven), pp. 555–566.
  • LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
  • PARMAR, D. and BURKA, L. T., 1991, Metabolism and disposition of cyclohexanone oxime in male F-344 rats. Drug Metabolism and Disposition, 19, 1101–1107.
  • PELLOCK, J. M., 1987, Carbamazepine side effects in children and adults. Epi/epsia, 28 (suppl. 3), 64-70. SCHUTZ, H., FELDMANN, K. F., FAIGLE, J. W., KRIEMLER, H. P. and WINKLER, T., 1986, The metabolism of 14C-oxcarbazepine in man. Xenobiotica, 16, 769–778.
  • SHORVON, S. D., 1996, The epidemiology and treatment of chronic and refractory epilepsy. Epi/epsia, 37 (suppl. 2), 1–3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.